Key result
Adipokines act as promising mediators in renal cell carcinoma biology, although their specific mechanisms of action in regulating tumor initiation and progression remain unclear.
Why the study?
While the role of adipokines in normal physiology is recognized, their biological functions in renal cell carcinoma remain partially understood.
This review highlights the emerging roles of adipokines in renal cell carcinoma biology and emphasizes the need for further mechanistic studies to enable targeted therapies.
INTRODUCTION: Adipokines are bioactive signaling molecules secreted from adipose tissue (AT) that have regulatory functions in maintaining metabolic homeostasis. In physiological conditions, balanced adipokine secretion supports metabolic stability and organ function. However, disruption of this balance can promote chronic inflammation and increase cancer risk. While their role in normal physiology is recognized, biological functions of adipokines in renal cell carcinoma (RCC) remain partially understood. AREAS COVERED: This review explores the biological functions of key adipokines such as adiponectin, leptin, visfatin, nesfatin-1, apelin, and omentin-1 in normal cellular processes and RCC. A search of the literature on PubMed, Web of Science, and Embase databases was performed from January 2000 through April 2025. This review summarizes findings on how these adipokines influence tumor biology, with a specific focus on their emerging roles in RCC. The review includes new findings and their possible limitations and the complexity of adipokine signaling and their roles in promoting or inhibiting tumorigenesis. EXPERT OPINION: The current evidence highlights adipokines as promising mediators in RCC biology; however, their mechanisms of action remain unclear. Further mechanistic studies are essential to unravel how adipokines regulate tumor initiation and progression. Without such understanding, the rational design of targeted therapies remains limited.
No takes yet. Share an insight, caveat, or question.
Chinapayan et al. (2025) conducted a review in Renal cell carcinoma (RCC). Adipokines was evaluated. Adipokines act as promising mediators in renal cell carcinoma biology, although their specific mechanisms of action in regulating tumor initiation and progression remain unclear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: